Aeras (www.aeras.org) is dedicated to the development of effective TB vaccines to prevent TB across all age groups in an affordable and sustainable manner. Aeras works globally in collaboration with numerous partners and stakeholders to support the development of vaccines and currently supports the development of six TB vaccine candidates, two of which are at the Phase IIb proof of concept stage of clinical trials in Africa.
Aeras is based in Rockville, Maryland, USA – where it operates a state-of-the-art manufacturing and laboratory facility – and in Cape Town, South Africa. Affordability and availability at the soonest possible date are key components of the Aeras approach to future access to new TB vaccines. The manufacturing facilities are adjacent to the Aeras development and research laboratory, offering the advantage of easy transfer of technology and knowledge from the laboratory to manufacturing and to ensure uniformity of quality, adequate supply, the lowest possible cost and the future elimination of lag time between licensure and distribution. Aeras offers contract manufacturing services to outside organizations and has completed numerous end-to-end CMO projects from process development through cGMP manufacturing (cell banking, fermentation/cell culture, purification) and fill/finish of clinical trial materials. To learn more about contract manufacturing visit: www.aeras-cmo.org.
DCVMN is a voluntary public health driven alliance of vaccine
manufacturers from developing countries that aims to make a consistent supply of high quality vaccines that are accessible to protect people against
known and emerging infectious diseases globally.